Quantitative SSTR-PET/CT: a potential tool for predicting everolimus response in neuroendoctine tumour patients

1. Auernhammer CJ, Spitzweg C, Angele MK, Boeck S, Grossman A, Nölting S, et al. Advanced neuroendocrine tumours of the small intestine and pancreas: clinical developments, controversies, and future strategies. Lancet Diabetes Endocrinol 2018; 6: 404–15. doi: 10.1016/s2213-8587(17)30401-1 AuernhammerCJ SpitzwegC AngeleMK BoeckS GrossmanA NöltingS Advanced neuroendocrine tumours of the small intestine and pancreas: clinical developments, controversies, and future strategies Lancet Diabetes Endocrinol 2018 6 404 15 10.1016/s2213-8587(17)30401-1 Open DOISearch in Google Scholar

2. Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 2017; 3: 1335–42. doi: 10.1001/jamaoncol.2017.0589 DasariA ShenC HalperinD ZhaoB ZhouS XuY Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States JAMA Oncol 2017 3 1335 42 10.1001/jamaoncol.2017.0589 Open DOISearch in Google Scholar

3. Klöppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann NY Acad Sci 2004; 1014: 13–27. doi: 10.1196/annals.1294.002 KlöppelG PerrenA HeitzPU The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification Ann NY Acad Sci 2004 1014 13 27 10.1196/annals.1294.002 Open DOISearch in Google Scholar

4. Briest F, Grabowski P. PI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasms. Theranostics 2014; 4: 336–65. doi: 10.7150/thno.7851 BriestF GrabowskiP PI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasms Theranostics 2014 4 336 65 10.7150/thno.7851 Open DOISearch in Google Scholar

5. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 514–23. doi: 10.1056/NEJMoa1009290 YaoJC ShahMH ItoT BohasCL WolinEM Van CutsemE Everolimus for advanced pancreatic neuroendocrine tumors N Engl J Med 2011 364 514 23 10.1056/NEJMoa1009290 Open DOISearch in Google Scholar

6. Lee L, Ito T, Jensen RT. Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence. Expert Opin Pharmacother 2018; 19: 909–28. doi: 10.1080/14656566.2018.1476492 LeeL ItoT JensenRT Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence Expert Opin Pharmacother 2018 19 909 28 10.1080/14656566.2018.1476492 Open DOISearch in Google Scholar

7. Akirov A, Larouche V, Alshehri S, Asa SL, Ezzat S. Treatment options for pancreatic neuroendocrine tumors. Cancers 2019; 11: 828. doi: 10.3390/cancers11060828 AkirovA LaroucheV AlshehriS AsaSL EzzatS Treatment options for pancreatic neuroendocrine tumors Cancers 2019 11 828 10.3390/cancers11060828 Open DOISearch in Google Scholar

8. Garcia-Carbonero R, Garcia-Figueiras R, Carmona-Bayonas A, Sevilla I, Teule A, Quindos M, et al. Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development. Cancer Metastasis Rev 2015; 34: 823–42. doi: 10.1007/s10555-015-9598-5 Garcia-CarboneroR Garcia-FigueirasR Carmona-BayonasA SevillaI TeuleA QuindosM Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development Cancer Metastasis Rev 2015 34 823 42 10.1007/s10555-015-9598-5 Open DOISearch in Google Scholar

9. Choi JI, Imagawa DK, Bhosale P, Bhargava P, Tirkes T, Seery TE, et al. Magnetic resonance imaging following treatment of advanced hepatocellular carcinoma with sorafenib. Clin Mol Hepatol 2014; 20: 218–22. doi: 10.3350/cmh.2014.20.2.218 ChoiJI ImagawaDK BhosaleP BhargavaP TirkesT SeeryTE Magnetic resonance imaging following treatment of advanced hepatocellular carcinoma with sorafenib Clin Mol Hepatol 2014 20 218 22 10.3350/cmh.2014.20.2.218 Open DOISearch in Google Scholar

10. Krajewski KM, Nishino M, Franchetti Y, Ramaiya NH, Van den Abbeele AD, Choueiri TK. Intraobserver and interobserver variability in computed tomography size and attenuation measurements in patients with renal cell carcinoma receiving antiangiogenic therapy: implications for alternative response criteria. Cancer 2014; 120: 711–21. doi: 10.1002/cncr.28493 KrajewskiKM NishinoM FranchettiY RamaiyaNH Van den AbbeeleAD ChoueiriTK Intraobserver and interobserver variability in computed tomography size and attenuation measurements in patients with renal cell carcinoma receiving antiangiogenic therapy: implications for alternative response criteria Cancer 2014 120 711 21 10.1002/cncr.28493 Open DOISearch in Google Scholar

11. Solis-Hernandez MP, Fernandez Del Valle A, Carmona-Bayonas A, Garcia-Carbonero R, Custodio A, Benavent M, et al. Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study). Br J Cancer 2019; 121: 537–44. doi: 10.1038/s41416-019-0558-7 Solis-HernandezMP Fernandez Del ValleA Carmona-BayonasA Garcia-CarboneroR CustodioA BenaventM Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study) Br J Cancer 2019 121 537 44 10.1038/s41416-019-0558-7 Open DOISearch in Google Scholar

12. Schmid-Tannwald C, Schmid-Tannwald CM, Morelli JN, Neumann R, Haug AR, Jansen N, et al. Comparison of abdominal MRI with diffusion-weighted imaging to 68Ga-DOTATATE PET/CT in detection of neuroendocrine tumors of the pancreas. Eur J Nucl Med Mol Imaging 2013; 40: 897–907. doi: 10.1007/s00259-013-2371-5 Schmid-TannwaldC Schmid-TannwaldCM MorelliJN NeumannR HaugAR JansenN Comparison of abdominal MRI with diffusion-weighted imaging to 68Ga-DOTATATE PET/CT in detection of neuroendocrine tumors of the pancreas Eur J Nucl Med Mol Imaging 2013 40 897 907 10.1007/s00259-013-2371-5 Open DOISearch in Google Scholar

13. Papotti M, Bongiovanni M, Volante M, Allìa E, Landolfi S, Helboe L, et al. Expression of somatostatin receptor types 1–5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch 2002; 440: 461–75. doi: 10.1007/s00428-002-0609-x PapottiM BongiovanniM VolanteM AllìaE LandolfiS HelboeL Expression of somatostatin receptor types 1–5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis Virchows Arch 2002 440 461 75 10.1007/s00428-002-0609-x Open DOISearch in Google Scholar

14. Versari A, Camellini L, Carlinfante G, Frasoldati A, Nicoli F, Grassi E, et al. Ga-68 DOTATOC PET, endoscopic ultrasonography, and multidetector CT in the diagnosis of duodenopancreatic neuroendocrine tumors: a single-centre retrospective study. Clin Nucl Med 2010; 35: 321–8. doi: 10.1097/RLU.0b013e3181d6677c VersariA CamelliniL CarlinfanteG FrasoldatiA NicoliF GrassiE Ga-68 DOTATOC PET, endoscopic ultrasonography, and multidetector CT in the diagnosis of duodenopancreatic neuroendocrine tumors: a single-centre retrospective study Clin Nucl Med 2010 35 321 8 10.1097/RLU.0b013e3181d6677c Open DOISearch in Google Scholar

15. Singh S, Poon R, Wong R, Metser U. 68Ga PET Imaging in patients with neuroendocrine tumors: a systematic review and meta-analysis. Clin Nucl Med 2018; 43: 802–10. doi: 10.1097/rlu.0000000000002276 SinghS PoonR WongR MetserU 68Ga PET Imaging in patients with neuroendocrine tumors: a systematic review and meta-analysis Clin Nucl Med 2018 43 802 10 10.1097/rlu.0000000000002276 Open DOISearch in Google Scholar

16. Pavel M, Öberg K, Falconi M, Krenning EP, Sundin A, Perren A, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020; 31: 844–60. doi: 10.1016/j.annonc.2020.03.304 PavelM ÖbergK FalconiM KrenningEP SundinA PerrenA Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol 2020 31 844 60 10.1016/j.annonc.2020.03.304 Open DOISearch in Google Scholar

17. Kim JY, Hong SM, Ro JY. Recent updates on grading and classification of neuroendocrine tumors. Ann Diagn Pathol 2017; 29: 11–6. doi: 10.1016/j.anndiagpath.2017.04.005 KimJY HongSM RoJY Recent updates on grading and classification of neuroendocrine tumors Ann Diagn Pathol 2017 29 11 6 10.1016/j.anndiagpath.2017.04.005 Open DOISearch in Google Scholar

18. Yao JC, Pavel M, Lombard-Bohas C, Cutsem EV, Voi M, Brandt U, et al. Everolimus for the treatment of advanced pancreatic neuroendocrine tumors: overall survival and circulating biomarkers from the randomized, Phase III RADIANT-3 study. J Clin Oncol 2016; 34: 3906–13. doi: 10.1200/jco.2016.68.0702 YaoJC PavelM Lombard-BohasC CutsemEV VoiM BrandtU Everolimus for the treatment of advanced pancreatic neuroendocrine tumors: overall survival and circulating biomarkers from the randomized, Phase III RADIANT-3 study J Clin Oncol 2016 34 3906 13 10.1200/jco.2016.68.0702 Open DOISearch in Google Scholar

19. Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 2016; 387: 968–77. doi: 10.1016/s0140-6736(15)00817-x YaoJC FazioN SinghS BuzzoniR CarnaghiC WolinE Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study Lancet 2016 387 968 77 10.1016/s0140-6736(15)00817-x Open DOISearch in Google Scholar

20. Cherk MH, Kong G, Hicks RJ, Hofman MS. Changes in biodistribution on (68)Ga-DOTA-Octreotate PET/CT after long acting somatostatin analogue therapy in neuroendocrine tumour patients may result in pseudoprogression. Cancer Imaging 2018; 18: 3. doi: 10.1186/s40644-018-0136-x CherkMH KongG HicksRJ HofmanMS Changes in biodistribution on (68)Ga-DOTA-Octreotate PET/CT after long acting somatostatin analogue therapy in neuroendocrine tumour patients may result in pseudoprogression Cancer Imaging 2018 18 3 10.1186/s40644-018-0136-x Open DOISearch in Google Scholar

21. Weber M, Telli T, Kersting D, Seifert R. Prognostic implications of PET-derived tumor volume and uptake in patients with neuroendocrine tumors. Cancers 2023; 15: 3581. doi: 10.3390/cancers15143581 WeberM TelliT KerstingD SeifertR Prognostic implications of PET-derived tumor volume and uptake in patients with neuroendocrine tumors Cancers 2023 15 3581 10.3390/cancers15143581 Open DOISearch in Google Scholar

22. Kratochwil C, Mavriopoulou E, Rath D, Afshar-Oromieh A, Apostolopoulos D, Haufe S, et al. Comparison of 68Ga-DOTATOC biodistribution in patients with and without spleenectomy. Q J Nucl Med Mol Imaging 2015; 59: 116–20. PMID: 24382404 KratochwilC MavriopoulouE RathD Afshar-OromiehA ApostolopoulosD HaufeS Comparison of 68Ga-DOTATOC biodistribution in patients with and without spleenectomy Q J Nucl Med Mol Imaging 2015 59 116 20 PMID: 24382404 Search in Google Scholar

23. Sarikaya I, Sarikaya A, Alnafisi N, Alenezi S. Significance of splenic uptake on somatostatin receptor imaging studies. Nucl Med Rev Cent East Eur 2018; 21: 66–70. doi: 10.5603/NMR.a2018.0012 SarikayaI SarikayaA AlnafisiN AleneziS Significance of splenic uptake on somatostatin receptor imaging studies Nucl Med Rev Cent East Eur 2018 21 66 70 10.5603/NMR.a2018.0012 Open DOISearch in Google Scholar

24. Schieren G, Bölke E, Scherer A, Raffel A, Gerber PA, Kröpil P, et al. Severe everolimus-induced steatohepatis: a case report. Eur J Med Res 2013; 18: 22. doi: 10.1186/2047-783x-18-22 SchierenG BölkeE SchererA RaffelA GerberPA KröpilP Severe everolimus-induced steatohepatis: a case report Eur J Med Res 2013 18 22 10.1186/2047-783x-18-22 Open DOISearch in Google Scholar

25. Kuhn B, Jacobsen W, Christians U, Benet LZ, Kollman PA. Metabolism of sirolimus and its derivative everolimus by cytochrome P450 3A4: insights from docking, molecular dynamics, and quantum chemical calculations. J Med Chem 2001; 44: 2027–34. doi: 10.1021/jm010079y KuhnB JacobsenW ChristiansU BenetLZ KollmanPA Metabolism of sirolimus and its derivative everolimus by cytochrome P450 3A4: insights from docking, molecular dynamics, and quantum chemical calculations J Med Chem 2001 44 2027 34 10.1021/jm010079y Open DOISearch in Google Scholar

26. Öksüz MÖ, Winter L, Pfannenberg C, Reischl G, Müssig K, Bares R, et al. Peptide receptor radionuclide therapy of neuroendocrine tumors with 90Y-DOTATOC: is treatment response predictable by pre-therapeutic uptake of 68Ga-DOTATOC? Diagn Interven Imaging 2014; 95: 289–300. doi: 10.1016/j.diii.2013.07.006 Öksüz MÖ, WinterL PfannenbergC ReischlG MüssigK BaresR Peptide receptor radionuclide therapy of neuroendocrine tumors with 90Y-DOTATOC: is treatment response predictable by pre-therapeutic uptake of 68Ga-DOTATOC? Diagn Interven Imaging 2014 95 289 300 10.1016/j.diii.2013.07.006 Open DOISearch in Google Scholar

27. Kratochwil C, Stefanova M, Mavriopoulou E, Holland-Letz T, Dimitrakopoulou-Strauss A, Afshar-Oromieh A, et al. SUV of [68Ga]DOTATOC-PET/CT predicts response probability of prrt in neuroendocrine tumors. Mol Imag Biol: 2015; 17: 313–8. doi: 10.1007/s11307-014-0795-3 KratochwilC StefanovaM MavriopoulouE Holland-LetzT Dimitrakopoulou-StraussA Afshar-OromiehA SUV of [68Ga]DOTATOC-PET/CT predicts response probability of prrt in neuroendocrine tumors Mol Imag Biol: 2015 17 313 8 10.1007/s11307-014-0795-3 Open DOISearch in Google Scholar

28. Sharma R, Wang WM, Yusuf S, Evans J, Ramaswami R, Wernig F, et al. (68) Ga-DOTATATE PET/CT parameters predict response to peptide receptor radionuclide therapy in neuroendocrine tumours. Radiother Oncol 2019; 141: 108–115. doi: 10.1016/j.radonc.2019.09.003 SharmaR WangWM YusufS EvansJ RamaswamiR WernigF (68) Ga-DOTATATE PET/CT parameters predict response to peptide receptor radionuclide therapy in neuroendocrine tumours Radiother Oncol 2019 141 108 115 10.1016/j.radonc.2019.09.003 Open DOISearch in Google Scholar

29. Kim YI, Yoo C, Oh SJ, Lee SJ, Kang J, Hwang HS, et al. Tumour-to-liver ratio determined by [(68)Ga]Ga-DOTA-TOC PET/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumours. EJNMMI Res 2020; 10: 63. doi: 10.1186/s13550-020-00651-z KimYI YooC OhSJ LeeSJ KangJ HwangHS Tumour-to-liver ratio determined by [(68)Ga]Ga-DOTA-TOC PET/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumours EJNMMI Res 2020 10 63 10.1186/s13550-020-00651-z Open DOISearch in Google Scholar

30. Sirico M, Bernocchi O, Sobhani N, Giudici F, Corona SP, Vernieri C, et al. Early changes of the standardized uptake values (SUV(max)) predict the efficacy of everolimus-exemestane in patients with hormone receptor-positive metastatic breast cancer. Cancers 2020; 12: 3314 doi: 10.3390/cancers12113314 SiricoM BernocchiO SobhaniN GiudiciF CoronaSP VernieriC Early changes of the standardized uptake values (SUV(max)) predict the efficacy of everolimus-exemestane in patients with hormone receptor-positive metastatic breast cancer Cancers 2020 12 3314 10.3390/cancers12113314 Open DOISearch in Google Scholar

31. Michl M, Lehner S, Paprottka PM, Ilhan H, Bartenstein P, Heinemann V, et al. Use of PERCIST for prediction of progression-free and overall survival after radioembolization for liver metastases from pancreatic cancer. J Nucl Med 2016; 57: 355–60. doi: 10.2967/jnumed.115.165613 MichlM LehnerS PaprottkaPM IlhanH BartensteinP HeinemannV Use of PERCIST for prediction of progression-free and overall survival after radioembolization for liver metastases from pancreatic cancer J Nucl Med 2016 57 355 60 10.2967/jnumed.115.165613 Open DOISearch in Google Scholar

32. Haug AR, Auernhammer CJ, Wangler B, Schmidt GP, Uebleis C, Goke B, et al. 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J Nucl Med 2010; 51: 1349–56. doi: 10.2967/jnumed.110.075002 HaugAR AuernhammerCJ WanglerB SchmidtGP UebleisC GokeB 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors J Nucl Med 2010 51 1349 56 10.2967/jnumed.110.075002 Open DOISearch in Google Scholar

33. Opalińska M, Morawiec-Sławek K, Kania-Kuc A, Al Maraih I, Sowa-Staszczak A, Hubalewska-Dydejczyk A. Potential value of pre- and post-therapy [68Ga] Ga-DOTA-TATE PET/CT in the prognosis of response to PRRT in disseminated neuroendocrine tumors. Front Endocrinol 2022; 13: 929391. doi: 10.3389/fendo.2022.929391 OpalińskaM Morawiec-SławekK Kania-KucA Al MaraihI Sowa-StaszczakA Hubalewska-DydejczykA Potential value of pre- and post-therapy [68Ga] Ga-DOTA-TATE PET/CT in the prognosis of response to PRRT in disseminated neuroendocrine tumors Front Endocrinol 2022 13 929391 10.3389/fendo.2022.929391 Open DOISearch in Google Scholar

34. Ingenerf M, Kiesl S, Karim S, Beyer L, Ilhan H, Rübenthaler J, et al. (68) Ga-DOTATATE PET/CT and MRI with diffusion-weighted imaging (DWI) in short- and long-term assessment of tumor response of neuroendocrine liver metastases (NELM) following transarterial radioembolization (TARE). Cancers 2021; 13: 4321. doi: 10.3390/cancers13174321 IngenerfM KieslS KarimS BeyerL IlhanH RübenthalerJ (68) Ga-DOTATATE PET/CT and MRI with diffusion-weighted imaging (DWI) in short- and long-term assessment of tumor response of neuroendocrine liver metastases (NELM) following transarterial radioembolization (TARE) Cancers 2021 13 4321 10.3390/cancers13174321 Open DOISearch in Google Scholar

35. O JH, Lodge MA, Wahl RL. Practical PERCIST: a simplified guide to PET response criteria in solid tumors 1.0. Radiology 2016; 280: 576–84. doi: 10.1148/radiol.2016142043 OJH LodgeMA WahlRL Practical PERCIST: a simplified guide to PET response criteria in solid tumors 1.0 Radiology 2016 280 576 84 10.1148/radiol.2016142043 Open DOISearch in Google Scholar

36. Ilan E, Velikyan I, Sandström M, Sundin A, Lubberink M. Tumor-to-blood ratio for assessment of somatostatin receptor density in neuroendocrine tumors using 68Ga-DOTATOC and 68Ga-DOTATATE. J Nucl Med 2020; 61: 217–21. doi: 10.2967/jnumed.119.228072 IlanE VelikyanI SandströmM SundinA LubberinkM Tumor-to-blood ratio for assessment of somatostatin receptor density in neuroendocrine tumors using 68Ga-DOTATOC and 68Ga-DOTATATE J Nucl Med 2020 61 217 21 10.2967/jnumed.119.228072 Open DOISearch in Google Scholar